Alzheimer's disease: The forgetting gene
The DOI matches its Crossref record; 10 of the 11 references it cites were found in a registry or an index, and 1 are not checked yet.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, those with the e4 form are more likely to have beta-amyloid accumulation and Alzheimer's dementia at a younger age than those with the e2 or e3 forms of the APOE gene.76,77”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, those with the e4 form are more likely to have beta‐amyloid accumulation and Alzheimer's dementia at a younger age than those with the e2 or e3 forms of the APOE gene.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Linnertz, C., Anderson, L., Gottschalk, W., Crenshaw, D., Lutz, M. W., Allen, J., Saith, S., Mihovilovic, M., Burke, J. R., Welsh‐Bohmer, K. A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.08.280 · Cited by 90
TOMM40 Association With Alzheimer Disease: Tales of APOE and Linkage Disequilibrium
Guerreiro, R. J., & Hardy, J. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1935 · Cited by 32
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“In addition, those with the 34 form are more likely to develop Alzheimer’s at a younger age than those with the 32 or 33 forms of the APOE gene [44].”
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
“In addition, those with the e4 form are more likely to develop Alzheimer’s at a younger age than those with the e2 or e3 forms of the APOE gene [65].”
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
“In addition, those with the e4 form are more likely to develop Alzheimer’s at a younger age than those with the e2 or e3 forms of the APOE gene [42].”
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
2017 Alzheimer's disease facts and figures
(2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,311
“In addition, those with the e4 form are more likely to develop Alzheimer’s at a younger age than those with the e2 or e3 forms of the APOE gene [43].”
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Hanamsagar, R., & Bilbo, S. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.039 · Cited by 374
“In late-onset AD, the most common form is the disease, having one form of the apoliportein A (APOE ε4) gene in chromosome 19 increases the risk of developing the disease (Spinney 2014).”
BackgroundInhibition of protein aggregation and amyloid formation by small molecules
Doig, A. J., & Derreumaux, P. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.12.004 · Cited by 298
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity
Abondio, P., Sazzini, M., Garagnani, P., Boattini, A., Monti, D., Franceschi, C., Luiselli, D., & Giuliani, C. (2019) · Genes · doi:10.3390/genes10030222 · Cited by 229
“The APOE genotype accounts for the vast majority of AD risk and AD pathology: inheriting one copy of APOE4 raises a person’s risk of developing the disease fourfold, while, with two copies, the risk increases 12-fold [64].”
BackgroundModeling neurodegeneration in Caenorhabditis elegans
Caldwell, K. A., Willicott, C. W., & Caldwell, G. A. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.046110 · Cited by 178
Alzheimer Disease and Its Growing Epidemic
Hickman, R. A., Faustin, A., & Wısnıewskı, T. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.009 · Cited by 201
Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155
“APOE ε2 is associated with a reduced risk of AD, while APOE ε3 has no effect and APOE ε4 increases the risk of AD development (Spinney, 2014).”
Amyloid β oligomers (AβOs) in Alzheimer’s disease
Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 157
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E.-K., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 125
Askanas, V., Engel, W. K., & Nogalska, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.005 · Cited by 120
“TOMM40 encodes the mitochondrial pore protein Tom40, which is involved in the transport of Aβ and other proteins into mitochondria [19], and its elongation has been postulated associated with the pathogenesis of AD [20].”
Orr, A. L., Kim, C., Jimenez-Morales, D., Newton, B. W., Johnson, J. R., Krogan, N. J., Swaney, D. L., & Mahley, R. W. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181184 · Cited by 103
Muszyński, P., Groblewska, M., Kulczyńska-Przybik, A., Kułakowska, A., & Mroczko, B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170208124324 · Cited by 99
“Moreover, the development of AD seems to occur in ε4 form carriers at younger age than in those with the presence of ε2 or ε3 allele of the APOE gene [17].”
BackgroundCellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“The mutations in presenilin1 (PS1), presenilin2 (PS2), and amyloid precursor protein (APP) genes are associated with the familial Alzheimer’s disease (FAD) (reviewed by Hardy [9]), while the presence of apolipoprotein E (APOE) ε4 genotype links to sporadic form of AD [10,11].”
BackgroundCaenorhabditis elegans as a Model System to Study Human Neurodegenerative Disorders
Roussos, A., Kitopoulou, K., Borbolis, F., & Palikaras, K. (2023) · Biomolecules · doi:10.3390/biom13030478 · Cited by 92
“Although APOEe2 isoform is linked with reduced risk, APOEe4 is connected with increased risk of disease development and has been suggested to exacerbate early- and late-onset forms of AD [47], whereas APOEe3 is neutral [48].”
BackgroundJanssen, C. I. F., Jansen, D., Mutsaers, M. P. C., Dederen, P. J. W. C., Geenen, B., Mulder, M. T., & Kiliaan, A. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155307 · Cited by 70
Ashford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 68
“One of the most important unresolved issues in AD study is the specific role of the APOE molecule [48, 49], including its evolution, its normal action relevant to neuroplasticity and AD, and how that action is differentially affected by the three common alleles— 2, 3, and 4, leading to a substantial increase of AD ris…”
BackgroundCai, Y., Sun, Z., Jia, H., Luo, H., Ye, X., Wu, Q., Xiong, Y., Zhang, W., & Wan, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00027 · Cited by 68
“(e.g., β-secretase and apolipoprotein E4) failed to fully explain the whole pathogenesis process of AD (Mullane and Williams, 2013; Spinney, 2014).”
BackgroundVeening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Boon, W. P. C., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172524 · Cited by 55
“(Mullane and Williams, 2019; Reardon, 2018; Spinney, 2014).”
Expression of BC1 Impairs Spatial Learning and Memory in Alzheimer’s Disease Via APP Translation
Zhang, T., Pang, P., Fang, Z., Guo, Y., Li, H., Li, X., Tian, T., Yang, X., Chen, W., Shu, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0820-z · Cited by 52
Why does the Aβ peptide of Alzheimer share structural similarity with antimicrobial peptides?
Pastore, A., Raimondi, F., Rajendran, L., & Temussi, P. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0865-9 · Cited by 48
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Alves, S., Fol, R., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.017 · Cited by 45
Griffin, E. F., Scopel, S. E., Stephen, C. A., Holzhauer, A. C., Vaji, M. A., Tuckey, R. A., Berkowitz, L. A., Caldwell, K. A., & Caldwell, G. A. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.037218 · Cited by 62
“Although estimates vary based on study and ethnicity, ∼ 40% of AD cases harbor the ε 4 allele of APOE (Spinney, 2014).”
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 47
“When it comes to identifying and quantifying intricate biological systems, an MS-based method is sensitive [65].”
Background2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 112
Scuto, M. C., Modafferi, S., Rampulla, F., Zimbone, V., Tomasello, M., Spanò, S. M., Ontario, M. L., Palmeri, A., Salinaro, A. T., Siracusa, R., et al. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111686 · Cited by 43
If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions?
Ooi, L., Dottori, M., Cook, A. L., Engel, M., Gautam, V., Grubman, A., Hernández, D., King, A. E., Maksour, S., Anastacio, H. T. D., et al. (2020) · The Neuroscientist · doi:10.1177/1073858420912404 · Cited by 35
“The importance of APOE4 has been known for more than 25 years (Qian and others 2017; Spinney 2014).”
BackgroundWagner, W. J., & Gross, M. L. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21814 · Cited by 38
Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Kakish, J., Lee, D., & Lee, J. S. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00172 · Cited by 39
Gozes, I., Yeheskel, A., & Pasmanik‐Chor, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142490 · Cited by 35
“Except for ApoE, mentioned above, the translocase of outer mitochondrial membrane 40 homolog, TOMM40 (with chromosomal localization close to ApoE and association with mitochondrial activity) was also suggested to be linked to AD (for review, please see [47]).”
BackgroundInnate immunity in Alzheimer’s disease: the relevance of animal models?
Franco Bocanegra, D. K., Nicoll, J. A. R., & Boche, D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 30
“Ageing and polymorphism of the apolipoprotein E (APOE) gene are the main risk factors for AD (McDowell 2001; Spinney 2014).”
BackgroundVillasana, L., Weber, S. J., Akinyeke, T. O., & Raber, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13737 · Cited by 28
“Among the major human isoforms of apolipoprotein E (apoE) involved in cholesterol and lipid metabolism, apoE4 (E4) is a risk factor to develop age-related cognitive decline and Alzheimer’s disease, particularly in women (Farrer et al. 1997; Raber et al. 2004; Spinney 2014).”
BackgroundLin, R., Zhang, Y., Yan, D., Liao, X., Gong, G., Hu, J., Fu, Y., & Cai, W. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.150 · Cited by 29
APOE – a genetic marker of comorbidity in subjects with morbid obesity
Farup, P. G., Rootwelt, H., & Hestad, K. A. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01082-2 · Cited by 25
Montufar-Armendariz, S., Calero, C., Vinueza‐Gavilanes, R., Correa, P., Carrera-Gonzalez, A., Villegas, F., Moreta, G., & Paredes, R. (2017) · International Journal of Alzheimer s Disease · doi:10.1155/2017/1059678 · Cited by 32
“The APOE ε4 allele has been related to earlier onset as well as higher risk for AD, and individuals with two copies of the APOE ε4 allele have a higher risk and earlier onset than heterozygous subjects [17].”
BackgroundMwendwa, P., LAWLOR, B. A., Kroll, T., & Brún, A. D. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03668-2 · Cited by 30
“Age is the most common risk factor for developing dementia [2] although it is not an inevitable part of ageing as those at younger ages can also develop dementia [3].”
BackgroundKong, C., Xie, H., Gao, Z., Shao, M., Li, H., Shi, R., Cai, L., Gao, S., Sun, T., & Li, C. (2019) · Virologica Sinica · doi:10.1007/s12250-019-00124-1 · Cited by 18
“People with the e4 allele are more likely to develop AD than those with the e2 or e3 allele (Spinney 2014).”
BackgroundZhu, L., Shu, H., Liu, D., Guo, Q., Wang, Z., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00289 · Cited by 19
“On the other hand, APOE ε4 allele is an acknowledged genetic factor of vulnerability for AD patients with dose-dependent effects on clinical phenotype (Spinney, 2014).”
BackgroundLiu, C., Xu, S., Liu, Q., Chai, H., Luo, Y., & Li, S. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01458-2 · Cited by 20
Honda, K., Saito, Y., Saito, H., Toyoda, M., Abe, R., Saito, T., Saido, T. C., Michikawa, M., Taru, H., Sobu, Y., et al. (2022) · SSRN Electronic Journal · doi:10.1016/j.neurobiolaging.2022.12.003 · Cited by 17
Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
Mousa, Y. M., Abdallah, I. M., Hwang, M., Martin, D. R., & Kaddoumi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60664-5 · Cited by 12
Alzheimer’s Disease Classification Using Genetic Data
Khanal, S., Chen, J., Jacobs, N., & Lin, A. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669730 · Cited by 11
Holden, S. J., Kundu, P., Torres, E. R. S., Sudhakar, R., Krenik, D., Grygoryev, D., Turker, M. S., & Raber, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.767558 · Cited by 11
“Compared to E3, E2 is protective with regard to AD risk (Raber et al., 2004; Spinney, 2014), more prevalent among centenarians, and associated with improved episodic memory performance, larger hippocampal volume, and reduced hippocampal atrophy (Chiang et al., 2010; Goldberg et al., 2020).”
BackgroundCakir, Z., Lord, S. J., Zhou, Y. M., Jang, G. Μ., Polacco, B. J., Eckhardt, M., Jimenez‐Morales, D., Newton, B. W., Orr, A. L., Johnson, J. R., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100541 · Cited by 13
The Janus-like Association between Proton Pump Inhibitors and Dementia
Papazoglou, A., Arshaad, M. I., Henseler, C., Daubner, J., Broich, K., Haenisch, B., & Weiergräber, M. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210929144740 · Cited by 8
Yin, S., Qi, H.-M., Wang, X., Zhang, P., Lu, Y., Wei, M., Li, P., Qi, G., Lou, Y., Lu, C., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000265 · Cited by 6
Frequencies of Apolipoprotein E polymorphism in Iraqi Kurdish population
Al-Jaf, S. M. A. (2021) · Meta Gene · doi:10.1016/j.mgene.2021.100867 · Cited by 8
Hu, W., Guo, Y., Wang, X., Cui, T., Li, C., Liu, R., & Yin, C. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109218 · Cited by 6
Villasana, L., Akinyeke, T. O., Weber, S. J., & Raber, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20603 · Cited by 5
Temussi, P. A., Tartaglia, G. G., & Pastore, A. (2021) · BioEssays · doi:10.1002/bies.202100031 · Cited by 6
“The non-symptomatic phase ofAD lasts often several years, a period duringwhich the peptides form plaques containing amyloid fibrils of Aβ[73].”
BackgroundPhytochemicals and Vitagenes for a Healthy Brain
Osakabe, N., Anfuso, C. D., Jacob, U. M., Sidenkova, A. P., Fritsch, T., Abdelhameed, A. S., Rashan, L. J., Wenzel, U., Calabrese, E. J., & Calabrese, V. (2024) · Healthy ageing and longevity · doi:10.1007/978-3-031-68513-2_11 · Cited by 4
Cognition in Patients With Memory Difficulties and Dementia Relative to APOE e4 Status
Hestad, K. A., Engedal, K., Horndalsveen, P. O., & Strand, B. H. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.686036 · Cited by 5
“…Alzheimer disease, altered lipoprotein profile, atherosclerosis and cardiovascular disease, type II diabetes, changes in the immune response, oxidative stress, quality of life, physical activity, and obesity (Spinney, 2014; Klimentidis et al., 2018; Abondio et al., 2019; Kulminski et al., 2019).”
BackgroundInfluentialBeyond APP, PSEN1, PSEN2, and APOE: What Else Does the Genome Tell Us?
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_16 · Cited by 4
O’Niel, A., Parkins, C. J., Pederson, A., Saltonstall, E., Bunnell, E., Aggarwal, R., Sandholm, P., Kessler, K., Harrison, H. F., Smith, J. R., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1600119 · Cited by 3
A Global Review on Alzheimer’s Disease
Natarajan., P., Mumthaj., P., Vijay., J., & Gokul., V. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v68i01.017 · Cited by 4
Xu, C. D., Acevedo, P., Lu, Y., Su, B., Ozuna, K., Padilla, V., Karithara, A., Mao, C., Navia, R. O., Piamjariyakul, U., et al. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6037 · Cited by 2
“B were measured longitudinally at 0 (designated as baseline), 12, 24, 36, and 48 months, respectively.”
MethodAn AS‐qPCR‐based method for the detection of Alzheimer's disease‐related SNPs
Chen, J., Shi, B., Li, Y., Feng, Y., Ni, J., Shi, J., Luo, C., Wang, J., & Tian, J. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30350 · Cited by 2
Cakir, Z., Lord, S. J., Zhou, Y., Jang, G. Μ., Polacco, B. J., Eckhardt, M., Jimenez‐Morales, D., Newton, B. W., Orr, A. L., Johnson, J. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.06.495052 · Cited by 2
“ApoE4 lowers the age of onset and increases the risk of developing AD, and considerable evidence indicates that apoE4 has a fundamental role in AD neurodegeneration (2, 3, 7 – 15).”
Chapleau, R. R., Martin, C. A., Hughes, S. R., Baldwin, J. C., Sladky, J. H., Sherman, P. M., & Grinkemeyer, M. D. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3867-7 · Cited by 1
Thirty Years After the Launch of the Amyloid Cascade Hypothesis: Is there a Shift of Gears at Last?
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_20 · Cited by 1
Chapleau, R. R., Martin, C. A., Hughes, S. R., Baldwin, J. C., Sladky, J. H., Sherman, P. M., & Grinkemeyer, M. D. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4654-9 · Cited by 1
Bezine, M. (2017) · theses.fr (ABES) · doi:10.70675/a634c389z7b07z4830zb56dzbf7b53a56944 · Cited by 1
Predictive Testing and Alzheimer Disease
Heger, N. E. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231159 · Cited by 1
Askanas, V., Engel, W. K., & Nogalska, A. (2014)
D’Andrea, M. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801979-5.00015-1
D’Andrea, M. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801979-5.00001-1
Surgery, Anesthesia, and Risk for the Development of Dementia
Velkers, C. (2018) · QSpace (Queen's University Library)
Antunes, M. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.100.2019.tde-04062019-002600
Imaging Mass Spectrometry for the Research of Alzheimer’s Disease
Ikegawa, M., Miyasaka, T., Kakuda, N., & Ihara, Y. (2016) · Journal of the Mass Spectrometry Society of Japan · doi:10.5702/massspec.s16-04 · Cited by 1
Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
Talegaonkar, S., Gautam, N., Varshney, V., Sharma, S., & Bhattacharyya, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_13
Xu, C. D., Acevedo, P., Lu, Y., Su, B., Padilla, V., Ozuna, K., Moreno, K., Karithara, A., Mao, C. X., Navia, O., et al. (2021) · doi:10.21203/rs.3.rs-194964/v1
“With one copy of APOE-ε4 (ε2/ε4 and ε3/ε4) and two copies of APOE-ε4 (ε4/ε4), risk of developing the disease rises 4-fold and 12-fold, respectively (Spinney 2014).”
BackgroundProteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases
Alexander, K. M., Morgado, I., & Liao, R. (2021) · Advances in biochemistry in health and disease · doi:10.1007/978-3-030-78799-8_12
Genetic Determinants of Human Longevity
Dato, S., Soerensen, M., & Rose, G. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-679-6 · Cited by 2
Selection of animal models for drug efficacy
Veening-Griffioen, D. H. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1605
Identification of Predictive Protein Signature in Mci and Ad in Body Fluids (Blood and Csf)Preprint
Baseer, J., & Zafar, S. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4646296
Genetic Predictors of Cognitive Decline and Labor Market ExitPreprint
Agerbo, E., Borgbjerg, A. K., Gupta, N. D., & Halliday, T. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5141346 · Cited by 1
Genetic Predictors of Cognitive Decline and Labor Market ExitPreprint
Borgbjerg, A. K., Agerbo, E., Gupta, N. D., & Halliday, T. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5147073
Oluwatunase, G. O., Okwute, P. G., Asafa, O. O., Oyeniran, D. A., & Ogenetega, O. B. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008845
Liu, C., Xu, S., Liu, Q., Chai, H., Luo, Y., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26574832
Mwendwa, P., LAWLOR, B. A., Kroll, T., & Brún, A. D. (2023) · Figshare · doi:10.6084/m9.figshare.22607251
Développement de formes vectorisables innovantes dans le cadre de maladies liées à l'âge
Iskandar, S. (2019) · theses.fr (ABES) · doi:10.70675/1d771122z75d0z4ba8z8ee6zbd1a858ffc38
Implication des polynucléaires neutrophiles au cours de la maladie d’Alzheimer et des tauopathies
Dong, Y. (2018) · theses.fr (ABES) · doi:10.70675/0542df04zd02ez4a58za844z605f237e8f0b
Modeling and analysis of spatiotemporal dynamics of patients with Alzheimer’s disease
Arbabyazd, L. (2021) · theses.fr (ABES) · doi:10.70675/b101b126z96c0z43d7z9500z89e423a07a72
Jenseits von APP, PSEN1, PSEN2 und APOE – was lehrt uns das Genom noch?
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_16
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_20
Bunnell, E., Saltonstall, E., Shanava, E., O’Niel, A., Pederson, A., Marla, S., Llamas, M. L. S., Garg, I., Chaudhari, M., Vodapally, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899626
Metadata
- Authors
- Spinney, L.
- Corresponding author
- Spinney, Laura
- Venue
- Nature
- Published
- 2014-06-04
- Volume
- 510
- Issue
- 7503
- Pages
- 26-28
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2023605278
- Cited by
- 98
- References
- 10
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 11 · 2021: 10 · 2020: 6 · 2019: 11 · 2018: 6 · 2017: 10 · 2016: 7 · 2015: 10 · 2014: 4
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genetic risk factors, gene discovery, memory loss
- MeSH terms
- Pioglitazone, Mitochondrial Precursor Protein Import Complex Proteins, Alleles, Alzheimer Disease, Animals, Chromosomes, Human, Pair 19, Clinical Trials as Topic, Humans, Hypoglycemic Agents, Mice, Transgenic, Mitochondria, Models, Biological, Case-Control Studies, Amyloid beta-Peptides, Age of Onset, Genetic Predisposition to Disease, Membrane Transport Proteins, Thiazolidinediones, Mice, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.